Skip to content
DataLookout
Menu

NCT07028008

Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 38 words
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 15, 2025 to Jul 2, 2025
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety evaluation
Timeframe: up to 6 months after TIL administration

Secondary (5)

Overall Response Rate
Duration of Response
Disease Control Rate
Progression Free Survival
Overall Survival

Arms and interventions

tumor-infiltrating lymphocyte (TIL) therapyExperimental

1\~100 x 10 9 cells, 1time, IV

Biologicals: tumor-infiltrating lymphocyte (TIL)

Sites

1 site in 1 country

  • Samsung Medical CenterSeoul, Gang-Nam, South Korea